Decreased expression of microRNA-126 is associated with poor prognosis in XXXX with @entity5 .

@entity1 @entity5 @entity10013 @entity3 @entity1349
BACKGROUND: MicroRNA-126( @entity10013 ) has been shown to be frequently down-regulated in a variety of @entity5 and act as a potential @entity5 suppressor. However, its correlations with the clinicopathological characters of @entity5 remain unclear. METHODS: TaqMan quantitative RT-PCR was used to determine the expression level of @entity10013 in tissue samples. The associations of @entity10013 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis was performed to analyze the association of @entity10013 expression with @entity1349 ( @entity1349 ) of @entity1 . Univariate and multivariate Cox regression analyses were performed. RESULTS: @entity10013 expression level in @entity1 @entity5 tissues was significantly lower than that in adjacent nontumorous tissues (mean        SD: 0.59        0.44 vs. 1.00        0.51, P   <   0.0001). Decreased @entity10013 expression in @entity5 was found to be significantly associated with lymphatic invasion (P   =   0.002), distant @entity3 (P   <   0.001), FIGO stage (P   =   0.009), and histological grade (P   =   0.005). Kaplan-Meier analysis showed that @entity1 with lower levels of @entity10013 had significantly poorer survival than those with higher expression of this miRNA in @entity1 , with a 5-year @entity1349 of 45.7% and 70.9%, respectively (P   =   0.002). Multivariate analysis revealed that @entity10013 expression (HR   =   3.97, 95% CI: 2.01-20.22; P   =   0.003) was independently associated with the @entity1349 . CONCLUSION: Our data suggests the potential of @entity10013 as a prognostic biomarker for @entity5 . VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_220.
